[go: up one dir, main page]

DK0874631T3 - Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse - Google Patents

Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse

Info

Publication number
DK0874631T3
DK0874631T3 DK97901052T DK97901052T DK0874631T3 DK 0874631 T3 DK0874631 T3 DK 0874631T3 DK 97901052 T DK97901052 T DK 97901052T DK 97901052 T DK97901052 T DK 97901052T DK 0874631 T3 DK0874631 T3 DK 0874631T3
Authority
DK
Denmark
Prior art keywords
valaciclovir
genital herpes
pharmaceutically acceptable
acceptable salt
suppression
Prior art date
Application number
DK97901052T
Other languages
Danish (da)
English (en)
Inventor
John Delehanty
Margaret L Smiley
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24399659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0874631(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0874631T3 publication Critical patent/DK0874631T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK97901052T 1996-01-19 1997-01-17 Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse DK0874631T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59944896A 1996-01-19 1996-01-19
PCT/EP1997/000192 WO1997025989A1 (fr) 1996-01-19 1997-01-17 Utilisation de valaciclovir dans la fabrication d'un medicament destine au traitement de l'herpes genital

Publications (1)

Publication Number Publication Date
DK0874631T3 true DK0874631T3 (da) 2004-03-22

Family

ID=24399659

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97901052T DK0874631T3 (da) 1996-01-19 1997-01-17 Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse

Country Status (12)

Country Link
EP (1) EP0874631B1 (fr)
JP (1) JP4097698B2 (fr)
AT (1) ATE254463T1 (fr)
AU (1) AU722304B2 (fr)
CA (1) CA2243237C (fr)
CY (1) CY2512B1 (fr)
DE (1) DE69726255T2 (fr)
DK (1) DK0874631T3 (fr)
ES (1) ES2210490T3 (fr)
PT (1) PT874631E (fr)
WO (1) WO1997025989A1 (fr)
ZA (1) ZA97400B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
ITMI20010009A1 (it) * 2001-01-03 2002-07-03 Menarini Ricerche Spa Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
CA2465928C (fr) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthese et purification de valacyclovir
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004000265A2 (fr) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
WO2007090595A1 (fr) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Formulations solides de chlorhydrate de valacyclovir
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
JP4669804B2 (ja) * 2006-03-28 2011-04-13 株式会社オーディオテクニカ コンデンサマイクロホン
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
WO2009031576A1 (fr) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. Procédé de fabrication de cristaux de chlorhydrate de valacyclovir
CN104188928B (zh) * 2014-09-17 2017-07-28 山东新时代药业有限公司 一种盐酸伐昔洛韦片剂及其制备方法
WO2020049536A1 (fr) * 2018-09-07 2020-03-12 Jubilant Generics Limited Compositions pharmaceutiques de valacyclovir ou de ses sels pharmaceutiquement acceptables
CN109651371B (zh) * 2018-12-31 2021-02-23 辰欣药业股份有限公司 一种盐酸伐昔洛韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CA2243237C (fr) 2008-09-02
EP0874631B1 (fr) 2003-11-19
PT874631E (pt) 2004-04-30
ES2210490T3 (es) 2004-07-01
DE69726255D1 (de) 2003-12-24
AU722304B2 (en) 2000-07-27
JP4097698B2 (ja) 2008-06-11
ZA97400B (en) 1997-11-13
WO1997025989A1 (fr) 1997-07-24
AU1443497A (en) 1997-08-11
CY2512B1 (en) 2005-12-23
CA2243237A1 (fr) 1997-07-24
EP0874631A1 (fr) 1998-11-04
DE69726255T2 (de) 2004-08-26
ATE254463T1 (de) 2003-12-15
JP2000503310A (ja) 2000-03-21

Similar Documents

Publication Publication Date Title
DK0874631T3 (da) Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
NZ508526A (en) Opioid formulations for treating pain
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
PL201411B1 (pl) Zastosowanie entekawiru do wytwarzania kompozycji farmaceutycznej
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
RU2000111506A (ru) Таблетки с пролонгированным выделением для лечения болезни паркинсона
JP2001500121A (ja) 神経障害性の痛みを治療する組成物を含む抗けいれん剤
CA2098738A1 (fr) Compositions d'oxycodone a degagement progressif
JPH02502278A (ja) とくに後天性免疫不全状態の処置のための、免疫調整及び抗ウイルス効果を有する医薬の調製におけるモルヒネ拮抗剤の使用
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2180178A1 (fr) Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
JPH08283148A (ja) うつ性症状改善剤
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
WO2003099214A3 (fr) Formulations de biguanide
BR0007991A (pt) Uso do composto ácido (e) -7- [ 4- (4-fluorofenil) -6-isopropil-2- [metil (metilsulfonil) amino] pirimidin -5-il] - (3r, 5s) -3,5-diidroxiept-6-enóico, ou de um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de preparação de uma composição farmacêutica, de redução dos nìveis de c-ldl e da razão de lipìdeo de c-ldl/ c-hdl, e, regime dosagem
CA2120001A1 (fr) Composition pharmaceutique a base de flavopereirine et son utilisation contre le vih
CA2368352A1 (fr) Procede de traitement de la neuro degenerescence
JP2003523385A5 (fr)
WO1992015315A1 (fr) Mode de traitement de l'herpes
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
PL325242A1 (en) Method of obtaining solid drug administration forms for very low dosage drugs